KSC
188100.00KRW
+1000.00 (+0.53%)
We have scored 82 news catalysts on Celltrion, Inc. (068270.KS) over the past 12 months. The biggest single-day move next to one of them came Mar 23, 2026, when 068270.KS closed −6.8%: “Nvidia's Jensen Huang Says He Thinks ‘We've Achieved AGI'”. Coverage across the window leans positive (average ticker sentiment +0.59). Most of the impact sits in sector technology and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Latest scored catalyst for 068270.KS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
43.1T
P/E
—
EPS
—
Beta
0.32
52W range
158500-239047.62
Day range
—
Open
—
Prev close
—
Volume
287.5K
Avg volume
696.8K
Dividend
714.29
IPO
2005-07-19
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Celltrion, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
